Top Research Highlights, Summer 2012


Every  day, Breakthrough T1D leverages the expertise and innovation of distinguished researchers from across the globe to support better treatments, prevention, and ultimately a cure for type 1 diabetes (T1D). In this issue of Top Research  Highlights, please read about news from the American Diabetes Association’s 72nd Scientific Sessions in Philadelphia in June 2012. The results of many  Breakthrough T1D-funded research initiatives were  presented at this major meeting, which convenes more  than  13,000 members of the international diabetes community.

This issue reports on an exciting step forward in the development of a stable liquid form of glucagon. In addition, we bring you news about two clinical studies using  human participants with T1D that showed a safe “real- world” trial  of an artificial pancreas system, and the first-time evaluation of a hypoglycemia-hyperglycemia minimizer system, which demonstrated successful blood-glucose control. Findings from the Breakthrough T1D-supported Joslin  50-Year Medalist Study showed protection from advanced eye disease in some subjects who  have been living with T1D for 50 years or more.  And, a study of individuals with T1D who have had pancreatic islet transplants demonstrated that a combination therapy may help reverse failure in the function of the transplanted cells.

We also share with you an update about events that just occurred in August—an important FDA approval for the drug Lucentis and an exciting new research initiative that Breakthrough T1D is supporting in the area of beta  cell encapsulation. Our mission aims to serve everybody with T1D—at all ages and stages  of the disease. Please enjoy reading about some of the ways that we are working tirelessly to make that happen.